FDA Discusses Clinical Path for Bausch + Lomb's Dry AMD Drug BL1243
1 report, 1 independent
Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bausch + Lomb Corporation announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD). This followed a constructive meeting with the FDA, which provided greater clarity on the clinical development path for the drug. The clinical program is expected to begin in 2027.
From simcoereformer.ca
Why it matters
If successfully developed and approved, BL1243 could offer a differentiated oral treatment option for patients with dry AMD. The success of this program could increase the strategic value of Bausch Health.
From simcoereformer.ca
Who's involved
- FDARegulatory body that held the meeting regarding the drug's clinical path.
- Bausch HealthParent company of Bausch + Lomb Corporation, whose drug pipeline is involved.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Bausch + Lomb's drug progress may influence Citigroup's investment outlookBausch + Lomb's drug progress may influence Citigroup's investment outlookPossible
- FDA clarity on BL1243 could boost Bausch Health's pipelineRegulatory clarity on BL1243 may boost Bausch Health's pipeline valuePossible
- Bausch + Lomb's potential oral AMD drug may increase competition for Eli LillyBausch + Lomb's potential oral AMD drug may increase competition for Eli LillyPossible